Incyte Corporation (INCY) Income Statement
An income statement shows a company's revenue, expenses, and profit over a reporting period.
Incyte Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutics in the United States, Europe, Canada, and Japan.
Total Revenue Chart for Incyte Corporation
Incyte Corporation (INCY) revenue for FY2025 was USD 5.1B, a 21.2% change from FY2024. Incyte Corporation's revenue grew from USD 300.0K in 1993 to USD 5.1B in 2025 (1713647.3% over 32 years). Earnings per share moved from USD -1.49 in 2011 to USD 1.52 in 2022. Revenue compound annual growth rate: 5-year CAGR of 14.0%, 10-year CAGR of 21.2%, 20-year CAGR of 38.3%.
Total Revenue (US Dollars)
R&D as % of Revenue
Compare with
Key Stats
- Market Cap
- $24.00B
- Implied Share Price
- $118.38
- Enterprise Value
- $19.95B
- Revenue (TTM)
- $5.82B
- EBITDA
- $1.94B
- Profit Margin
- 27.71%
- Trailing P/E
- 15.27
- Forward P/E
- 38.76
- Price/Book (MRQ)
- 3.85
- Price/Sales (TTM)
- 4.12
- EV/EBITDA
- 9.65
- EV/Revenue
- 3.43
- Dividend Yield
- —
- Book Value
- $31.57
- Free Cash Flow (FY2025)
- $1.35B
- Free Cash Flow Yield
- 5.65%
Snapshot as of 7th August 2026 — not point-in-time controlled, may lag the live market by a few days.